1 Major Problem for the Cannabis Industry The Internet has empowered people to do their own research on medical issues. Unfortunately, a lot of the information those people find is flat-out wrong. And for companies hoping to capitalize on the marijuana derivative cannabidiol, or CBD, that misinformation could pose a serious risk. Marijuana has legitimate medical uses, and some CBD-based products have shown clinical evidence and/or won FDA approval for treating illnesses, including some rare but severe forms of epilepsy found in children. But different strains of cannabis affect different people in different ways. And despite reams of Internet hype, there's no evidence that CBD has any effect on the host of other maladies it supposedly combats, including and especially cancer. At best, early studies suggest one of the flavonoids in cannabis might be able to treat pancreatic cancer in mice — a long, long, loooooong way from an actual wonder drug for humans. If sky-high claims online eventually flip CBD's image from magical cure-all to total snake oil, the few companies that really are making useful drugs from CBD could suffer. For more on what investors should watch for in the budding cannabis-derived pharmaceutical space, read the rest.
|
No comments:
Post a Comment